- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| Fr | Civitas Social Housing - Strong financial and social returns continuing | 147 | H120 results showed strong year-on-year growth in rental income and earnings. Dividend cover is increasing and full cover is in sight, with debt facilities in place to fund further portfolio growth... ► Artikel lesen | ||
| Fr | Auriant Mining - Tardan CIL de-risks Kara-Beldyr | 100 | After a few months of delays, Auriant Mining's Tardan CIL project has now been operating since mid-November. Production guidance for FY19 is 550kg from the Tardan heap leach operation and 150kg from... ► Artikel lesen | ||
| Do | Fidelity European Values - Disciplined process driving outperformance | 107 | Fidelity European Values (FEV) is managed by Sam Morse, who selects stocks on a bottom-up basis, focusing on quality companies with strong balance sheets that are able to grow dividends over the long... ► Artikel lesen | ||
| Do | 4imprint Group - Self-promotion pays | 131 | 4imprint's pre-close update indicates trading in the later weeks of the full year continued strong, with FY19 results set to be at the higher end of the market forecast range. Revenue (+17%) was slightly... ► Artikel lesen | ||
| Mi | Secure Trust Bank - Positive pre-close | 93 | Secure Trust Bank's (STB) pre-close trading update indicates that FY19 results should be in line with expectations, despite the economic slowdown dampening loan demand in the second half of 2019. STB... ► Artikel lesen | ||
| Mi | Games Workshop Group - 'Record sales and profit' again | 166 | Games Workshop's (GAW) interim results are ahead of expectations. The highest rates of revenue growth were achieved in the channels with the highest operating margins, ie Trade (40% margin) and Online... ► Artikel lesen | ||
| Di | Paion - Acacia to sell ByFavo in US | 854 | Acacia Pharma will sell ByFavo (remimazolam) in the US after a deal with Cosmo (Paion's Switzerland-based US partner). Cosmo estimates 24.5m endoscopy procedures per year. Acacia may launch its first... ► Artikel lesen | ||
| Di | IQE - Leading innovation from within | 142 | The breadth of IQE's technology portfolio and ability to serve compound semiconductor chip customers in the US and Asia puts it in a good position to benefit from rising demand for compound semiconductor... ► Artikel lesen | ||
| Di | Osirium Technologies - Bookings ahead of expectations | 111 | Osirium made good progress in signing new business in H2, reporting FY19 bookings 13% ahead of our forecast and 53% higher year-on-year. FY19 revenue is slightly below our forecast due to the timing... ► Artikel lesen | ||
| Di | Carr's Group - Engineering pipeline to offset weather challenges | 94 | Carr's trading update for the first 18 weeks of FY20 notes that while trading in Agriculture was lower than expected, primarily because of the mild UK weather, the strong Engineering pipeline should... ► Artikel lesen | ||
| Di | Deutsche Beteiligungs - Guidance beat assisted by a successful exit | 187 | NAV to be up to 10% lower (vs the current €472.1m as defined by DBAG), but more than 20% higher income from the fund services segment (FY19: €3.0m). The latter should be driven by the recent launch... ► Artikel lesen | ||
| Di | Boku - Payments profits support Identity growth | 93 | Boku's FY19 trading update confirmed that it met consensus expectations for revenue and EBITDA, albeit aided by recognition of one-off revenues of $3.2m in H2. The Payments business showed strong underlying... ► Artikel lesen | ||
| Di | Gamesys Group - Top end of consensus | 110 | Gamesys has reported a positive pre-close trading update following a strong final quarter. The company expects FY19 pro-forma revenue and adjusted EBITDA to reach the top end of consensus estimates... ► Artikel lesen | ||
| Mo | Acacia Pharma - ByFavo deal to bolster pipeline | 136 | Acacia Pharma has announced a deal with Cosmo Pharmaceuticals to acquire the US rights to registrational phase asset ByFavo (remimazolam). The deal strengthens Acacia's product offering beyond key asset... ► Artikel lesen | ||
| Mo | Kazia Therapeutics - An agile pivot | 196 | Kazia Therapeutics has announced that GDC-0084, its promising glioblastoma drug, will join (subject to definitive agreement) the pivotal GBM AGILE trial. AGILE is a clinician-led trial that currently... ► Artikel lesen | ||
| Mo | Henderson Far East Income - Access to Asian growth with solid 6% yield | 102 | Henderson Far East Income (HFEL) performed strongly in 2019, unusually outperforming a rising market while continuing to achieve a well-covered dividend and a yield in excess of 6%. The trust, managed... ► Artikel lesen | ||
| Mo | Shield Therapeutics - Feraccru out-licensed in China | 147 | Shield Therapeutics has kick-started 2020 by securing an out-licensing deal in China for its primary asset, Feraccru/Accrufer. The exclusive deal with China-based Beijing Aosaikang Pharmaceutical (ASK... ► Artikel lesen | ||
| Mo | XP Power - Demand acceleration through Q419 | 127 | While previously reported issues with an ERP upgrade limited the amount of product XP could ship in Q419, revenues for FY19 came in ahead of our forecast and XP closed the year with a strong order book... ► Artikel lesen | ||
| 10.01. | EQS Group - Compliance with growth story | 196 | EQS is making progress on its journey to become a fully embedded provider of investor relations and compliance platforms and products to corporate customers. While conversion of sales leads has been... ► Artikel lesen | ||
| 10.01. | Rockhopper Exploration - Sea Lion funding outlook strengthened | 199 | Rockhopper (RKH) has announced that, together with Premier Oil, it has signed Heads of Terms with Navitas Petroleum to farm down a 30% interest in the Sea Lion project. The deal increases confidence... ► Artikel lesen | ||
| 09.01. | Fluence Corporation - Financial close for Ivory Coast | 135 | Fluence has announced financial close on its Ivory Coast project. While there was little doubt this would be achieved at some point, it reduces uncertainty and enables at least US$20m in revenue to... ► Artikel lesen | ||
| 09.01. | Silence Therapeutics - Solving disease by targeting genes with siRNA | 158 | We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics... ► Artikel lesen | ||
| 08.01. | Greggs - 'A very strong finish to a spectacular year' | 138 | Greggs finished 2019 with accelerating revenue growth. It continues to benefit from increasing customer growth as the brand strengthens and it takes share in the 'food-on-the-go' market. With increased... ► Artikel lesen | ||
| 08.01. | 1Spatial - Update suggests performance is on track | 134 | 1Spatial's update suggests the momentum the business was enjoying at the time of the capital markets day in October has been sustained to the end of the calendar year. While no financial figures are... ► Artikel lesen | ||
| 08.01. | Avacta Group - New JV gives further validation to Affimers | 138 | Avacta has announced a joint venture with Daewoong Pharmaceuticals to develop mesenchymal stem cell (MSC) therapies incorporating Affimers. The joint venture (JV), will be based in South Korea and entirely... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
